Abbott Settles Key Preterm Infant Formula Lawsuits for $670 Million, Reducing Legal Overhang
ABT sits 39% above its 52-week low of $81.97.
Summary
Abbott has settled a major portion of its preterm infant formula litigation for $670 million, resolving the high-profile Gill case and 2,000 other claims, which significantly reduces a key legal risk.
Key Events · Legal and Risk Events · ABT
-
Litigation Settlement
Abbott agreed to pay approximately $670 million to resolve the "Gill" lawsuit and claims from about 2,000 other individuals related to its preterm infant formulas.
-
Risk Reduction
This settlement addresses a significant legal overhang, including the $495 million "Gill" verdict (plus interest, totaling ~$600M) that was affirmed on appeal, converting a contingent liability into a fixed cost.
-
Remaining Claims
Approximately 1,700 lawsuits involving 12,700 individual infants are still pending in federal and state courts, indicating ongoing, albeit reduced, legal exposure.
Analysis · ABT · Life Sciences
Abbott Laboratories has agreed to pay approximately $670 million to resolve the significant "Gill" lawsuit, which had an affirmed $495 million verdict, and an additional 2,000 related claims concerning its preterm infant formulas. This settlement, while a substantial payout, removes a major legal uncertainty and caps a previously elevated risk, as noted in the company's recent 10-Q. However, approximately 1,700 lawsuits involving 12,700 infants remain pending.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $113.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $197.5B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.